Validated biomarker assays confirm ARID1A loss is confounded with MMR deficiency, CD8 TIL infiltration, and provides no independent prognostic value in endometriosis‐associated ovarian carcinomas

2021 ◽  
Author(s):  
Karolin Heinze ◽  
Tayyebeh M. Nazeran ◽  
Sandra Lee ◽  
Pauline Krämer ◽  
Evan S. Cairns ◽  
...  
Keyword(s):  
Prognostic Value ◽  
Ovarian Carcinomas ◽  
Mmr Deficiency

scholarly journals Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas

2004 ◽  
Vol 15 (10) ◽  
pp. 1535-1542 ◽  
Author(s):  
C. Faleiro-Rodrigues ◽  
I. Macedo-Pinto ◽  
D. Pereira ◽  
C.S. Lopes
Keyword(s):  
Prognostic Value ◽  
Ovarian Carcinomas ◽  
E Cadherin

P53 and bcl-2 assessment in serous ovarian carcinoma

2008 ◽  
Vol 18 (2) ◽  
pp. 241-248 ◽  
Author(s):  
J. E. Palmer ◽  
L. J. Sant Cassia ◽  
C. J. Irwin ◽  
A. G. Morris ◽  
T. P. Rollason
Keyword(s):  
Prognostic Value ◽  
Disease Free Survival ◽  
Ovarian Tumors ◽  
Early Event ◽  
Low Grade ◽  
Ovarian Carcinomas ◽  
Study Objective ◽  
P53 Expression ◽  
Response To Chemotherapy ◽  
Clinicopathologic Parameters

The study objective was to determine the prognostic value of assessment of staining of p53 and bcl-2 in a well-selected group of serous ovarian carcinomas. Immunohistochemical detection was used to identify both p53 and bcl-2 positive tumors. One hundred thirty-two tumors were analyzed for positivity of staining, grade of staining intensity, and for p53 alone, percent expression rates. These were analyzed alongside traditional clinicopathologic parameters for their ability to predict overall survival (OS), disease-free survival (DFS), and response to chemotherapy (CR). Univariate COX analysis revealed percent p53 expression (P= 0.012) and p53 grade (P= 0.01) to be significant predictors of DFS. Neither the p53 nor bcl-2 measurement parameters were found significant for OS or prediction of CR. On multivariate analysis, incorporating clinicopathologic parameters, p53 parameters did not retain independent significance for any outcome measure. As in primary reported studies, bcl-2 was not found to be of clear independent prognostic value in this group of ovarian tumors. If mutation of p53 and its consequent overexpression is an early event in ovarian tumorigenesis, then p53 assessment may prove useful prognostically in the assessment of either low-grade ovarian carcinomas, as a possible indicator for progression, or in early-stage ovarian tumors, as a marker of tumor aggression or likelihood of recurrence. p53 analysis of a larger group of stage I ovarian tumors would be desirable to further explain the potential association with DFS.

scholarly journals Protein Expression and Prognostic Value of Genes in the erb-b Signaling Pathway in Advanced Ovarian Carcinomas

2005 ◽  
Vol 124 (3) ◽  
pp. 392-401 ◽  
Author(s):  
Yun Wang ◽  
Gunnar B. Kristensen ◽  
Åslaug Helland ◽  
Jahn M. Nesland ◽  
Anne-Lise Børresen-Dale ◽  
...  
Keyword(s):  
Protein Expression ◽  
Signaling Pathway ◽  
Prognostic Value ◽  
Ovarian Carcinomas

Prognostic Value of Histologic Grading of Ovarian Carcinomas

2003 ◽  
Vol 22 (1) ◽  
pp. 52-56 ◽  
Author(s):  
Yuichiro Sato ◽  
Tomihiro Shimamoto ◽  
Satoshi Amada ◽  
Yujiro Asada ◽  
Tohru Hayashi
Keyword(s):  
Prognostic Value ◽  
Ovarian Carcinomas ◽  
Histologic Grading

scholarly journals Prognostic Value and Immunohistochemical Analysis of Mismatch Repair Deficiency in Patients with Stage II and III Colorectal Carcinoma—A Single-Center Study

Medicina ◽  
2020 ◽  
Vol 56 (12) ◽  
pp. 676
Author(s):  
Tijana Denčić ◽  
Miljan Krstić ◽  
Aleksandar Petrović ◽  
Maja Jovičić-Milentijević ◽  
Goran Radenković ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Colorectal Carcinoma ◽  
Mismatch Repair ◽  
Prognostic Value ◽  
Young Patients ◽  
Immunohistochemical Analysis ◽  
Stage Ii ◽  
Single Center ◽  
Mmr Deficiency ◽  
Disease Free

Background and objectives: Deficient mismatch repair (MMR) status is associated with good prognosis but poor therapeutic response to adjuvant chemotherapy in patients with colorectal cancer. However, there are some opposed arguments considering therapeutic outcomes in patients with evidenced MMR deficiency in colorectal cancer. The aim of the study was the investigation of prognostic value and immunohistochemical analysis of the MMR-deficiency tumors. Materials and Methods: The study enrolled 104 patients with resected stage II and III colorectal cancer samples from the period 2018–2019. Results: The tumors with deficient MMR status were significantly associated with age up to 50 years and right-sided localization (p < 0.001). During the follow-up period of 22.43 ± 6.66 months, 21 patients (20.2%) died, whereas 14 patients (13.5%) had relapses. The loss of mutL homologue 1/postmeiotic segregation increased 2 (MLH1/PMS2) expression, compared to proficient MMR tumors, was associated with shorter disease-free survival in patients with lymphovascular invasion (p < 0.05), perineural invasion (p < 0.01), stage III (p < 0.05) and high-grade tumor (p < 0.05). Conclusions: This retrospective pilot study of a single-center cohort of patients with stage II and III colorectal cancer highlights the clinical importance of using immunohistochemistry (IHC) analysis as a guide for diagnostic algorithm in a country with limited resources, but with a high prevalence of colorectal carcinoma in the young patients. MMR-deficiency tumors compared with proficient MMR colorectal cancer was not shown to be a significant predictor of disease-free and overall survival.

Occurrence of epidermal growth factor receptors in human adnexal tumors and their prognostic value in advanced ovarian carcinomas

1988 ◽  
Vol 29 (2) ◽  
pp. 147-157 ◽  
Author(s):  
Thomas Bauknecht ◽  
Michael Runge ◽  
Michael Schwall ◽  
Albrecht Pfleiderer
Keyword(s):  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Prognostic Value ◽  
Growth Factor Receptors ◽  
Epidermal Growth Factor Receptors ◽  
Ovarian Carcinomas ◽  
Epidermal Growth ◽  
Adnexal Tumors

Prognostic Value of P-glycoprotein and Proliferative Index in Advanced Low Grade Serous Ovarian Carcinomas

2003 ◽  
Vol 15 (4) ◽  
pp. 380-386 ◽  
Author(s):  
M.R. Raspollini ◽  
G. Amunni ◽  
A. Villanucci ◽  
G. Baroni ◽  
V. Boddi ◽  
...  
Keyword(s):  
Prognostic Value ◽  
Low Grade ◽  
Proliferative Index ◽  
Ovarian Carcinomas ◽  
P Glycoprotein

scholarly journals Stromal Expression of MARCKS Protein in Ovarian Carcinomas Has Unfavorable Prognostic Value

2017 ◽  
Vol 19 (1) ◽  
pp. 41 ◽  
Author(s):  
Raoudha Doghri ◽  
Maroua Manai ◽  
Pascal Finetti ◽  
Maha Driss ◽  
Emilie Agavnian ◽  
...  
Keyword(s):  
Prognostic Value ◽  
Ovarian Carcinomas ◽  
Marcks Protein

354 EGF receptors and ornithine decarboxylase: Prognostic value in ovarian carcinomas

1983 ◽  
Vol 19 ◽  
pp. 118
Author(s):  
T. Bauknecht ◽  
W. Kleine ◽  
H.G. Meerpohl
Keyword(s):  
Ornithine Decarboxylase ◽  
Prognostic Value ◽  
Egf Receptors ◽  
Ovarian Carcinomas

Prognostic value of p53 accumulation in epithelial ovarian carcinomas

2002 ◽  
Vol 266 (4) ◽  
pp. 205-209 ◽  
Author(s):  
B. Berker ◽  
I. Dunder ◽  
A. Ensari ◽  
S. D. Cengiz
Keyword(s):  
Prognostic Value ◽  
Ovarian Carcinomas ◽  
Epithelial Ovarian Carcinomas
Sign in / Sign up

Export Citation Format

Share Document